ALX Oncology
ALXO
76 hedge funds and large institutions have $160M invested in ALX Oncology in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 10 closing their positions.
1,557% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $61K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
1% more funds holding
Funds holding: 75 → 76 (+1)
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.03% less ownership
Funds ownership: 83.91% → 80.88% (-3%)
38% less capital invested
Capital invested by funds: $258M → $160M (-$97.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.21M |
| 2 |
Morgan Stanley
New York
|
+$492K |
| 3 |
BlackRock
New York
|
+$294K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$246K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.75M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.92M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$991K |
| 4 |
Millennium Management
New York
|
-$672K |
| 5 |
Goldman Sachs
New York
|
-$264K |
ALXO Hedge Fund Activity: Q3 2023 in Review
76 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2023, worth a combined $160M — down 38% from $258M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALXO positions and 10 closed out — a net gain of 2 holders — while 23 added to existing stakes and 22 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1.21M. The largest seller was Artal Group, exiting entirely with an estimated $3.75M sold.
- 76 institutional investors held ALX Oncology (ALXO) as of Q3 2023, up from 75 in Q2 2023.
- Funds reported $160M of ALX Oncology stock for Q3 2023, down 38% quarter-over-quarter.
- 12 funds opened new ALX Oncology positions in Q3 2023 and 10 closed out, a net change of +2 holders.
- The largest ALX Oncology buyer in Q3 2023 was Citadel Advisors, an estimated $1.21M added.
- The largest ALX Oncology seller in Q3 2023 was Artal Group, an estimated $3.75M sold.
Based on aggregated 13F filings for Q3 2023.